The journal
Open the journal →The conversation starts in the journal — be the first to post.
About FibroGen (United States)
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
Everything about FibroGen (United States) →- Country
- United States
- Headquarters
- San Francisco
- Inception
- January 1, 1993
- Website
- http://www.fibrogen.com/